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Creation of an autologous arteriovenous ﬁstula (AVF) for vascular access in haemodialysis is the modality of
choice. However neointimal hyperplasia and loss of the luminal compartment result in AVF patency rates of
~60% at 12 months. The exact cause of neointimal hyperplasia in the AVF is poorly understood. Vascular trauma
has long been associated with hyperplasia. With this in mind in our rabbit model of AVF we simulated cannula-
tion autologous to that undertaken in vascular access procedures and observed signiﬁcant neointimal hyperpla-
sia as a direct consequence of cannulation. The neointimal hyperplasia was completely inhibited by topical
transdermal delivery of the non-steroidal anti-inﬂammatory (NSAID) diclofenac. In addition to the well docu-
mented anti-inﬂammatory properties we have identiﬁed novel anti-proliferative mechanisms demonstrating
diclofenac increases AMPK-dependent signalling and reduced expression of the cell cycle protein cyclin D1. In
summary prophylactic transdermal delivery of diclofenac to the sight of AVF cannulation prevents adverse
neointimal hyperplasic remodelling and potentially offers a novel treatment option that may help prolong AVF
patency and ﬂow rates.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Vascular access is the Achilles heel of modern haemodialysis [1]. The
complications of vascular access are responsible for over 20% of all
hospitalisations of patients on haemodialysis and account for one
third of all in-patient renal bed usage [2]. Autologous arteriovenous
ﬁstulae created from native artery and vein are the modality of choice
to provide vascular access for haemodialysis. Unfortunately however,
native ﬁstulae have poor patency rates. Recently, a systematic review
and meta-analysis on AVF patency was published using rigorous meth-
odology to examine 62 unique cohorts [3]. The authors reported that
one-quarter to one-third of AVF failed to mature, and by one year 40%
of all AVF had failed or required intervention. The hallmark of AVF
failure is neointimal hyperplasia leading to stenosis with occlusion of
the ﬁstula outﬂow vein [4,5].
The mechanisms leading to AVF stenosis are not fully understood
however interplay between the vascular wall and immune system are
important. Cytokines and pro-inﬂammatory factors have been shown
to play central roles in the activation of acute and chronic vascular re-
sponse to injury [6]. For example enhanced NFκB activation has been
shown to result in the expression of a number of pro-inﬂammatory
genes in vitro including iNOS, COX-2, ICAM, VCAM, which have been
strongly implicated in neointimal formation [7]. Patients with renal dis-
ease undergoing haemodialysis have a raised inﬂammatory proﬁle with
signiﬁcantly increased hs-CRP, serum TNF-α, IL-1, MCP-1, VCAM-1 and
ICAM-1, aswell as increased expression of the pro-inﬂammatory recep-
tor TLR-4 [8–10].
Vascular injury as a consequence of angioplasty or stent insertion is
well documented [11]. Central to the haemodialysis procedure is double
cannulation of the AVF with a 14/15 G (1.4/1.6 mm diameter) stainless
needle 2–3 times every week. The acute trauma inﬂicted by the needle
piercing the vascular wall likely releases numerous pro-inﬂammatory
mediators which promote both wound healing and neointimal growth.
There are many studies highlighting the role of pro-inﬂammatory pro-
cesses in vein graft failure [12]. The known key signalling pathways
driving vascular neointimal proliferation are the mitogen-activated
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protein kinase (MAPK) pathways; extracellular signal-regulated kinases
1/2 (ERK1/2), c-Jun amino-terminal kinases (JNKs) and the p38MAPKs
[13]. Phosphorylation of ERK ismainly associatedwith a proliferative re-
sponse to a mitogenic stimulus, whereas p38 MAPK and JNK pathways
are activated by stressors such as hypoxia or injury [14]. Cell prolifera-
tion like all active processes within the cell is regulated by a number
of upstream co-dependent cellular bioenergetic regulating proteins. A
key regulator of cell bioenergetics is AMP-activated protein kinase
(AMPK) [15]. Cell energy requirements are signiﬁcantly raised during
cell proliferation and consequently AMPK is activated during AMP:
ATP cycling [16].
Currently there are no prophylactic treatments to reduce the pro-
gression of neointimal hyperplasia and thrombus formation in AVFs.
Percutaneous transluminal angioplasty of stenosis in functioning fore-
arm AVF has been shown to signiﬁcantly improve patency and decrease
access-relatedmorbidity [17]. However, the disadvantages of these pro-
cedures are that they require frequent revision as the 12month patency
rate can be as low as 26% [18]. The option of pharmacotherapy to reduce
AVF stenosis in this patient group is also challenging. Co-morbidities,
impaired hepatic metabolism, profoundly impaired or no renal excre-
tion and adverse bleeding events limit this as a clinically viable option
[19].
The considered use of non-steroidal anti-inﬂammatory drugs
(NSAIDs) which have anti-proliferative and anti-inﬂammatory activity
may offer a potential option as an interventional treatment for AVF
neointimal hyperplasia and thrombus formation. Thus the aim of this
study was to investigate for the ﬁrst time the efﬁcacy of transdermal
delivery of the NSAID diclofenac in reducing neointimal hyperplasia
and thrombus formation as a consequence of cannulation-dependent
injury of the AVF.
2. Materials and methods
2.1. Creation of the femoral arteriovenous ﬁstula
Ethical approval for the use of animals in this study was obtained
from University of Strathclyde Ethics Committee. The licence to under-
take in-vivo work was granted by the UK Home Ofﬁce in accordance
with the Animals (Scientiﬁc Procedures) Act 1986.
Rabbits (New Zealand White) were given a pre-medication of
hypnorm (0.3 ml/kg, VetaPharma Ltd., UK) intramuscularly 15 min
prior to surgery. During surgery the rabbit's body temperature, res-
piration and heart beat were visually observed and recorded. Based
on respiration and heart rate, the concentration of isoﬂurane was ad-
justed between 1 and 1.5%. Subcutaneous Rimadyl (4 mg/kg, Pﬁzer,
UK) was also given at the time of surgery. A site proximal to the
right knee was chosen to create the AVF due to the superﬁcial nature
of the vessels. The subsartorial femoral artery and vein were
mobilised and ﬂushed with IV heparin 1000 units given via the mar-
ginal ear vein. The vessels were controlled with (8 mm) clamps and
5 mm longitudinal arteriotomy and venotomy performed. A side-to-
side anastomosis using 10–0 polyamide suture (Ethicon, USA) was
created. The distal vein was then ligated using a 4–0 polyamide su-
ture (Ethicon, USA) to ensure unidirectional blood ﬂow through
the vein, in effect creating an end to side anastomosis.
2.2. Ultrasonography of arteriovenous ﬁstula
Ultrasound measurements were performed using a Philips Sono
5500 and a linear array probe (6–15mHz) 10 days following arteriove-
nous creation. Brightness mode (B-mode) ultrasound was used to
visualise the patency of vessels and to measure vessel diameter. Pulsed
Wave Doppler mode was used to measure the blood velocity. Blood
ﬂow (ml/min) was calculated.
2.3. Cannulation injury and diclofenac application
Cannulation injury to the venous branch of the AVF was performed
three times a week during days 28–56 by the same individual. Needle
stick injury was conﬁned to an area of 1–1.5 cm along the outﬂow
vein, mimicking the area cannulation technique used clinically. A saline
charged 23 gauge needle was inserted into the vein for 60 s after which
the needle was withdrawn and pressure placed on the AVF. At the time
of cannulation, ultrasound was used to ensure placement of the needle
within the vein. No ﬂow was applied through the cannula. Diclofenac
diethylammonium gel (1.16%, Novartis, UK) was applied topically to
the AVF cannulation site in treatment group animals days 28–56.
Animals received 750 mg (equivalent to 1 mg/cm2 dose of diclofenac)
twice a day.
2.4. Measurement of serum diclofenac
Analysis of the samples was carried out by injecting 10 μl onto an
ACE C18 column (3 mm × 150 mm, 3 μm, HiChrom, Reading UK) with
a mobile phase consisting of 1 mM acetic acid in water/1 mM acetic
acid in acetonitrile (30:70) at a ﬂow rate of 0.4 ml/min. The run time
was 7 min. Detection was carried out by using an Orbitrap Exactive in-
strument in negative ion mode with a needle voltage of −4 kV and
sheath gas and auxiliary gases set at 50 and 17 arbitrary units respec-
tively. The instrument was scanned between 100 and 700 amu and
tuned so that the accurate masses of the analytes were within 3 ppm
of the exact masses.
Calibration curves were constructed by spiking 20 ng of ﬂurbiprofen
(IS) into 6 × 0.5 ml aliquots of serum and a series consisting of 0, 1, 2, 4,
8, 16 ng of diclofenac. The protein was then precipitated by adding
0.5 ml of acetonitrile, centrifuging and removing the supernatant for
analysis. Aliquots of the biological samples (0.2 ml) were treated in
the same way but were spiked with 8 ng of IS and protein was precipi-
tatedwith 0.2ml of acetonitrile. The 0 point showed no interfering peak
for diclofenac and the 1 ng/0.5ml spike showed a clear peakwith a peak
height of around 50,000. The cut off point for the trap is 5000 so the limit
of detection was 0.1 ng/0.5 ml.
2.5. Histological processing of rabbit AVF
Following euthanasia by intravenous injection of sodium pentobar-
bital (1 ml/kg), the animal's vessels were perfusion ﬁxed with 4% para-
formaldehyde. The AVF and contralateral control vessels were removed
with surrounding muscle still attached and placed in fresh 4% parafor-
maldehyde solution. Tissues were then wax processed and cut at 5 μM
before being stained with haematoxylin and eosin.
2.6. Vascular smooth muscle cell culture
Femoral vein was isolated from white New Zealand rabbits. Mouse
wild type and AMPKα1−/− aortas were isolated from 8 week old
sv129 mice. Vessels were cut into rings and VSM cell explants cultured
in 1:1 waymouths: ham's F12 (Gibco, UK) with 15% foetal calf serum
(FCS) (Biosera, France), 1% penicillin streptomycin (Gibco, UK at 37 °C,
5% CO2, 100% humidity).
2.7. 3H-thymidine incorporation assay
Cell proliferation was determined using serum-induced [
3
H]-thymi-
dine incorporation as described previously [20]. Quiesced cells were
stimulated with 10% FCS for 24 h, with the addition of 1 μCi/well of 3H
thymidine (Amersham, UK) for the ﬁnal 6 h. Cells were washed with
ice cold PBS and four washes of 10% trichloroacetic acid. Thereafter
cells were solubilised with 250 μl lauryl sulphate (10%) plus sodium
hydroxide (0.2 M). The contents of each well were then transferred to
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a vial and radioactivity quantiﬁed by liquid scintillation in DPM-1 using
a Packard 1500 Tri-Carb (PerkinElmer, USA).
2.8. Immunoblotting of VSM cell lysates
Treated/stimulated VSM cells were washed with ice cold PBS and
lysed by addition of boiling sample buffer (0.125 M Tris–HCl (pH 6.7),
0.5 mM Na4P2O7, 1.25 mM EDTA, 1.25% (v/v) glycerol, 0.5% (w/v) SDS,
25 mM dithiothreitol and 0.02% (w/v) bromophenol blue). Samples
were loaded on to a 10% SDS page gel (minimum of 20 μg total protein
per well), and following electrophoresis proteins were transferred to a
nitrocellulose membrane. Membranes were blocked for 1 h at room
temperature in 3% BSA and incubated overnight in the following pri-
mary antibodies (1:1000); anti-phospho/Total ERK rabbit IgG (Cell
Signalling Technology, USA), anti-phospho/Total p38 rabbit IgG
(Cell Signalling Technology, USA), anti-Cyclin D1 rabbit IgG (Santa
Cruz Biotechnology Inc., USA), anti-GAPDH mouse IgG (Cell Signal-
ling Technology, USA), anti-phospho/Total AMPK rabbit IgG (Cell
Signalling Technology, USA), and anti-phospho/Total ACC rabbit
IgG (Cell Signalling Technology, USA). For detection of the primary
antibody, a HRP-conjugated anti-rabbit IgG at 1/2000 dilution (Cell
Signalling Technology, USA) or anti-mouse IgG at 1:10,000 dilution
(Stratech Scientiﬁc Ltd, UK) was used. The blots were developed
using an enhanced chemiluminescence kit (Thermo Scientiﬁc Peirce,
USA).
2.9. Statistical analysis
All in vitro results are shown as themean relative to control. Minitab
wasused to carry out statistical analysis,with p b 0.05 considered signif-
icant. A general linear ANOVA model with cells from each separate
animal entered as a random factor was used to assess the effect of
Fig. 1. Creation and maturation of rabbit femoral AVF. A, AVF between the femoral artery and vein. The anastomosis was created by continuous suture (10–0) in a side to side fashion,
followed by ligation of the distal vein. B, B-mode ultrasound was used to visualise patency of the AVF following creation. C, Pulsed Wave Doppler was used to measure the velocity of
bloodwithin the AVF. A pulsatile waveformwas present in the vein, indicating successful ﬂow of arterial blood through the AVF. D, Over 4 weeks post-AVF creation, venous lumen diam-
eter and E, peak blood ﬂow signiﬁcantly increased. Results are shown as themean± S.E.M., n= 11, *= p b 0.05 (paired T-test for day 10 vs. day 30). F, Histological examination (H&E) of
the anastomosis 8 weeks following AVF creation reveals healthy integration of both vessels with intact vascular wall. Scale bar = 200 μm, A = artery, V = vein.
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increasing diclofenac concentrations; and post hoc Dunnett's used to
assess the signiﬁcance of speciﬁc treatments vs. control. Paired and
unpaired T-tests were used for single comparisons, and a one way
ANOVA used for comparison of multiple groups within in-vivo studies.
3. Results
3.1. Conformation of AVF function and maturation
Following the creation of an AVF between the femoral artery and
vein, blood ﬂow was restored to allow arterial blood to enter directly
into the femoral vein as shown in Fig. 1A. Patency and lumen diameter
of both vessels was monitored by cross sectional B-mode ultrasound
(Fig. 1B). Over the ﬁrst 4 weeks post-AVF creation, venous lumen diam-
eter showed a small increase (Fig. 1D). The velocity of blood within the
vein, measured by PulsedWave Doppler, revealed a pulsatile waveform
originating from the artery (Fig. 1C). Using these techniques, blood ﬂow
through the vein was calculated (Fig. 1E). At the end of the maturation
period there was a signiﬁcant time dependent rise in blood ﬂow,
increasing from 42.1 ± 5.0 ml/min at days 10 to 60.5 ± 7.2 ml/min at
day 28. At the end of each study, vessels were perfusion ﬁxed in situ
and stained using H&E. Fig. 1F shows an example of the anastomosis
site revealing healthy integration of the artery and vein with intact
vascular wall with no focal remodelling or thrombosis.
3.2. Effect of needle cannulation and diclofenac treatment on AVF structure
and function
In the second phase of the study, animals were split into a control,
non-cannulated group, a group that underwent cannulation and a
group that underwent cannulation and diclofenac treatment. The effect
of AVF creation, cannulation and diclofenac intervention on vascular
remodellingwithin the venous branchof theAVFwas assessed histolog-
ically (Fig. 2). The creation of an AVF resulted in a signiﬁcant increase in
mean veinwall width from 10.5±0.9 μm to 16.6± 1.6 μm(Fig. 2B & E).
In the cannulation group there was a signiﬁcant 2.8 fold increase in vein
wall thickness vs. non-cannulated control (Fig. 2C &E). This remodelling
consisted of an increased cellular component as well as degradation of
the vein wall at the adventitial side of the media. In the cannulation
plus diclofenac treatment group there was a signiﬁcant three fold de-
crease in vein wall thickness when compared to cannulation alone
(Fig. 2D & E). Serum concentration of diclofenac measured on days 29
and 56 were 1.6 ± 1.4 and 74.1 ± 14.8 ng/l respectively.
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Fig. 2. Shows venous wall remodelling following creation of AVF A, control un-operated femoral vein, B, AVF, C, AVF with cannulation injury and D, injured AVFwith diclofenac treatment
(scale bar A–D = 50 μm, L = lumen). E, Vascular remodelling was quantiﬁed by measuring vein wall thickness for each group (deﬁned in examples by bar). Creation of an AVF was
associated with a small but signiﬁcant increase in remodelling. Injury resulted in a signiﬁcantly higher degree of remodelling which was inhibited by topical application of diclofenac.
Results are shown as the mean ± S.E.M. n = 7, 7, 6 & 6 for control, AVF, AVF + Injury and AVF + Injury + Diclofenac respectively. # = p b 0.05 unpaired T-test for unoperated control
vs. AVF, * = p b 0.05 one way ANOVA with post hoc Bonferroni's correction for AVF vs. AVF + Injury & AVF + Injury vs. AVF + Injury + Diclofenac.
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3.3. Effect of diclofenac on rabbit VSM cell proliferative mechanisms
The anti-proliferative activity of diclofenac on rabbit VSM cells was
analysed by 3H-thymidine incorporation. Based on reported anti-
proliferative concentrations diclofenac pre-treatment [5 μM–170 μM]
caused a concentration dependent decrease in 3H-thymidine incorpora-
tion as shown in Fig. 3A [21]. Further to this the effect of diclofenac on
MAPK kinase activation was investigated by immunoblot (Fig. 3B).
Under basal conditions phosphorylation of ERK was high, although the
cells still had the capacity for further phosphorylation when stimulated
by 10% FCS. Diclofenac pre-treatment had no effect on FCS stimulated
ERK activation. Under basal conditions p38was not expressed. However
upon stimulation with 10% FCS both total and phosphorylated p38 in-
creased which, like the ERK response, was not affected by diclofenac.
As it has been previously demonstrated that diclofenac causes an
accumulation in G1 of the cell cycle, cyclin D1 expression was also in-
vestigated (Fig. 3C) [21]. Diclofenac caused a signiﬁcant dose dependent
decrease in cyclin D1 expression leading to a 60% reduction at the
highest concentration (170 μM).
3.4. Effect of diclofenac on AMPK signalling
The effect of diclofenac on AMPK phosphorylation, and activation of
downstream ACC was assessed. Phosphorylation of AMPK was detected
under basal conditions (Fig. 4A) and increased signiﬁcantly following
diclofenac treatment in a dose dependentmanner. At 175 μMdiclofenac,
AMPK phosphorylation increased by 13 fold when compared with un-
treated controls (Fig. 4B). In addition, increased phosphorylation of the
AMPK substrate ACC was evident (Fig. 4A). Phosphorylation of ACCα
and ACCβ isoforms were detected and total pACC was increased by 24
fold vs. untreated controls following treatment with 175 μM diclofenac
(Fig. 4B).
3.5. The role of AMPK in the modulation of proliferation by diclofenac
To conﬁrm the role of AMPK in the anti-proliferative activity
of diclofenac, the pharmacological AMPK inhibitor compound C
was assessed. Treatment with compound C (10 μM) signiﬁcantly re-
duced AMPK phosphorylation by 49% (Fig. 4C). Downstream of this,
diclofenac mediated phosphorylation of ACC by AMPK was also
reduced by 60% (Fig. 4C). Following conﬁrmation of AMPK inhibition
by compound C, the effect of this inhibitor on the activity of diclofenac
was assessed using 3H thymidine incorporation. Surprisingly, 10 μM
compound C alone caused cell proliferation to reduce to baseline levels
(Fig. 4D) without affecting cell viability as assessed by trypan blue ex-
clusion (Fig. 4E). On further investigation, compound C was shown to
inhibit ERK phosphorylation, indicating an effect non-speciﬁc to AMPK
(Fig. 4F).
As compound C exhibited AMPK-independent activity, an alterna-
tive approach to inhibit AMPK by siRNA repression was attempted.
However, consistent rundown of AMPK could not be achieved and this
method proved unsuitable (data not presented). In order to circumvent
this issue, VSM cells were explanted and cultured from sv129 wild type
and AMPKα1−/− mouse aortas. In addition to mouse genotyping,
expression of AMPKα was carried out (Fig. 5A). As expected, cells
explanted from AMPKα1−/− aortas had signiﬁcantly reduced levels of
AMPKα expression. Having conﬁrmed this reduction in AMPK, the
effect of diclofenac treatment on 3H thymidine incorporation in of
wild type vs. AMPKα1−/− cells was assessed (Fig. 5B). Diclofenac
(85 μM) inhibited wild type cell proliferation by 52%. In contrast, cell
proliferation was only inhibited by 6% inhibition in AMPKα1−/− cell
(p = 0.001). Interestingly, when AMPKα1−/− cells were treated with
170 μM diclofenac, cell viability was dramatically reduced. This was,
not the case in the wild type cells (data not presented).
4. Discussion
In this study we have investigated the effect of repeated needle-
dependent injury on AVF structure and function. The function of the AVF
for vascular access in haemodialysis is dependent on high blood ﬂow
and thus a patent lumen is vital to this procedure. In this study we have
demonstrated for theﬁrst time that theprocedural practice of cannulation,
as used in gaining vascular access in haemodialysis, drives a vascular pro-
liferative response resulting in luminal occlusion, reduced blood ﬂow and
ultimately failure in terms of vascular access and haemodialysis (Fig. 2).
In our rabbit model as expected the vein section of the AVF
underwent an adaptive remodelling response following creation of the
ﬁstula and the introduction of arterial blood pressure/ﬂow. Cannulation
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Fig. 3. Shows the effect of diclofenac on key cell signalling events associatedwith cell pro-
liferation. A, QuiescedVSM cells were treatedwith diclofenac and stimulated for 24 hwith
10% FCS. Proliferation, measured by 3H thymidine incorporation, was reduced by
diclofenac treatment in a concentration dependent manner (general linear ANOVA,
p b 0.05). Results are shown as the mean relative to control ± S.E.M., n = 4, * =
p b 0.05 (post-hoc Dunnett's vs. control). B, Diclofencac treated VSM cells were stimulated
with 10% FCS for 15 min and immunoblotting was carried out for ERK or p38 phosphory-
lation. Diclofenac had no effect on the activation of these MAPK. C, Following diclofenac
treatment and stimulation with 10% FCS for 8 h, cyclin D1 expression was reduced in a
concentration dependentmanner. Results are shown as themean± S.E.M., n= 6, general
linear ANOVA p b 0.05, * = post-hoc Dunnett's vs. control p b 0.05.
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injury in a frequency similar to thatwhich is undergone in dialysis caused
a signiﬁcant increase inwall thickness at the cannulation site. In the unin-
jured AVFs no such remodelling was observed thus indicating cannula-
tion injury may be central to the adverse remodelling and focal stenosis
observed clinically in AVFs. Re-stenosis in response to vascular injury in-
cluding angioplasty, stent insertion and surgery is well established and
there are a number of established pharmaco-therapeutic interventions
to counteract restenosis [21,22]. However what is noteworthy about re-
stenosis and occlusion in patients with renal failure and AVFs is the
rapid time to occlusion when compared with lower limb or coronary re-
stenosis events [3].When considered, this patient cohort on renal dialysis
with a documented raised inﬂammatory proﬁle as a consequence of
uraemia related factors and other co-morbidities combined with the fre-
quent and sustained needle insertion may go some way to explain the
rapid progression to AVF occlusion [23,24].
To date there is no prophylactic intervention to offset the adverse
remodelling associated with needle cannulation injury. In terms of
pharmacotherapy we considered that this patient group would have
greatly reduced renal function. We therefore opted for transdermal
delivery at the site of needle cannulation in our experimental animal
model. NSAIDs have previously been demonstrated to be of worth in
this patient cohort in terms of increasing AVF patency. However, there
exists no convincing evidence to suggest that oral NSAIDs, such as
aspirin, alter the underlying mechanism of intimal hyperplasia, but
instead have a minor beneﬁt by inhibiting thrombosis. In this present
study, transdermal delivery of diclofenac resulted in a signiﬁcant
reduction of needle-dependent-AVF remodelling when compared
with untreated AVFs (Fig. 2). This, to the best of our knowledge is the
ﬁrst time that such a potential treatment intervention has been demon-
strated. The transdermal route of delivery offers a number of
advantages; site directed, permeates the vascular wall, reduces toxicity/
adverse bleeding and importantly the patient where appropriate can
self-administer.
The approved maximum daily dose for Voltaren Gel 1% is 32 g
(1280 mg diclofenac equivalent) and is less than the highest daily
dose tested by Kienzler et al (2010) who compared diclofenac
Fig. 4. Shows the effect of diclofenac on the AMPK-dependent signalling pathway. A, Following a 24 hour incubation with diclofenac, phosphorylated AMPK, and downstream ACC, in-
creased in a concentration dependent manner. B, Densitometry of AMPK blots, results are shows as the mean relative to untreated control, ±S.E.M., n = 6, * = p b 0.05 (general linear
ANOVA with post-hoc Dunnett's vs. control). C, AMPK antagonist compound C inhibits diclofenac mediated activation of AMPK and ACC. D, In contrast to what was expected compound
C reduces cell proliferation (n = 4, * = p b 0.05 paired T-test), E, without effecting cell viability (n = 4) F, via AMPK independent inhibition of ERK (n = 3, * = p b 0.05 paired T-test).
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bioavailability of oral vs. topical routes of administration [25]. In this
present study 2 g (80 mg equivalent diclofenac) applied topically to
the cannulation site had profound effect on the adverse remodelling.
However, with complete inhibition of cannulation-dependent remodel-
ling with the dose delivered, albeit relatively low, this could potentially
be further reduced in an attempt to ﬁnd a true minimum effect dose.
The prescribing of NSAIDs for subjects undergoing dialysis is greatly dis-
couraged [26]. Preservation of any residual renal function, as well as
avoiding adverse bleeding, are primary concerns. We were encouraged
that wemeasured ng/l quantities of diclofenac in serum from our rabbit
model. The amounts measured are in keeping with published human
studies [25]. In terms of preservation of residual renal function and
adverse bleeding further reducing the topically applied dose would be
welcomed and may with further work potentially allow such practice
to be adopted clinically.
In the present study we have conﬁrmed diclofenac mediated inhibi-
tion of VSM cell proliferation (Fig. 3A). The anti-proliferative mecha-
nism of diclofenac is independent of the classic mitogenic signalling
pathway ERK and p38 as diclofenac had no effect on phosphorylation
of either component (Fig. 1B). Previously diclofenac has been shown
to cause cell cycle arrest via activation of p53 leading to increased p21
[21]. The expression of cell cycle G1 associated cyclin D1 following
diclofenac treatment was assessed in this study. Cyclin D1 is essential
for cell cycle progression [27]. Diclofenac caused a concentration depen-
dent decrease in cyclin D1 expression (Fig. 3C). The concentrations
required for this activity (42.5–170 μM) were similar to those required
for inhibition of VSM cell proliferation thus strongly indicating that
diclofenac inhibits cell proliferation by reducing G1 associated cyclins,
possibly via the p53–p21 pathway. The reported anti-proliferative IC50
of diclofenac required for anti-proliferative activity is 170 μM, which is
vastly higher than the IC50 required for inhibition of COX-2 at 50 nM
[21,28]. This conclusion supports the hypothesis that inhibition of cell
proliferation by diclofenac is via a COX-independent means.
AMPK has previously been implicated in the NSAID aspirin's anti-
proliferative activity [28]. In this studywehave for theﬁrst timedemon-
strated that diclofenac mediates anti-proliferative activity through
AMPK signalling. A diclofenac-dependent increase in AMPK phosphory-
lationwasmeasured (Fig. 4A). To demonstrate progression of the AMPK
pathway, phosphorylation of downstream protein ACC was also
analysed. ACC is directly phosphorylated by AMPK to regulate the
metabolism of fatty acids within the cell, but not thought to be involved
in the regulation of cell cycle [29]. Diclofenac treatment resulted in a
signiﬁcant concentration dependent increase in ACC phosphorylation
(Fig. 4A). The response generated was greater than that seen for
AMPK activation, with an increase in phosphorylation occurring follow-
ing 20 μM diclofenac treatment. Similar effects have been reported for
aspirin and nifedipine, both of which activate AMPK causing ampliﬁed
ACC activation [29-31].
To conﬁrm the AMPK-dependent mechanism of action of diclofenac,
a number of approacheswere taken to block AMPK. Firstly, a pharmaco-
logical approach was taken using the AMPK antagonist compound C.
This agent signiﬁcantly inhibited diclofenac mediated AMPK activation,
as well as downstream activation of ACC (Fig. 4C). The effect of com-
pound C on diclofenac's anti-proliferative activity was evaluated. Initial
experiments assessed the effect of compound C alone. In contrast to
what was expected, compound Cwas shown to inhibit cell proliferation
(Fig. 4D) suggesting that it may have a cytotoxic effect on the cells, or
may have cellular substrates in addition to AMPK. However the viability
of cells was not affected by compound C treatment, as demonstrated by
trypan blue (Fig. 4E). Therefore the possibility that compound C may
have non-AMPK speciﬁc effects was assessed. ERK, a component of a
key signalling event in cell proliferation, was investigated. Compound
C signiﬁcantly inhibited FCS stimulated ERK phosphorylation (Fig. 4F).
Importantly, this was in contrast to diclofenac treatment which had
no effect on ERK (Fig. 4B). Thus compound C has AMPK independent
effects and can reduce proliferation via inhibition of ERK.
Murine wild type and AMPKα1−/− VSM cells where utilised to
assess the impact of AMPK on diclofenacmediated inhibition of prolifer-
ation. This demonstrated for the ﬁrst time that AMPKα1 was essential
for diclofenac mediated activity. However, this study has not assessed
the mechanism through which diclofenac activates AMPK. It is likely
that the mechanism is similar to aspirin mediated allosteric activation
of AMPK via binding of the beta subunit. As this is the ﬁrst report of
diclofenac mediated AMPK activation further studies are needed to
establish this hypothesis.
5. Conclusions
This study has a number of novel observations; we have demon-
strated that diclofenac causes a concentration dependent inhibition of
VSM cell proliferation. The mechanisms of action are via an increase in
AMPK phosphorylation and reduced expression of the cell cycle protein
cyclin D1 and surprisingly, are independent of ERK/p38 mitogenic
signalling. The mechanism of action underlying effects of diclofenac
was conﬁrmed in murine wild type and AMPKα1−/− VSM cells where
diclofenac mediated inhibition of proliferation was shown to be reliant
on AMPKα1. However, the mechanism through which diclofenac acti-
vates AMPK is yet to be elucidated. The primary observation in this
study was in our successful model of AVF creation in the adult rabbit.
We have successfully demonstrated that cannulation results in cumula-
tive injury that signiﬁcantly contributes to adverse remodelling and
luminal occlusion in the vein section of the surgically created AVFs.
Importantly we have further demonstrated that prophylactic transder-
mal delivery of diclofenac to the AVF cannulation sight prevents
cannulation-dependent remodelling. Further study is nonetheless re-
quired to deﬁne minimum effective dosage thus ensuring preservation
of any residual kidney function in this vulnerable patient group.
Fig. 5. Highlights the AMPKα1-dependent action of diclofenac. A, VSM cells were
explanted form wild type and AMPKα1−/− sv129 mouse aorta. AMPKα1 knock out was
conﬁrmed by immunoblotting. B, Mouse VSM cells were treated with 85 μM diclofenac
for 24 h before being stimulated with 10% FCS. AMPKα1−/− VSM cell proliferation was
not affected by diclofenac treatment, unlike wild type proliferation which was reduced
by half. Proliferation was measured by 3H thymidine incorporation and expressed as the
mean relative to control, ± S.E.M., n = 4, * = p b 0.05 (unpaired T-test).
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However this novel use of NSAIDs may offer a treatment option and if
adopted could potentially prolong AVF patency.
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